ERIC KHOO SG
2021-12-28
Dont spread fud please
China's Kintor says interim analysis of COVID treatment trial misses statistical criteria
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696829532,"tweetId":"696829532","gmtCreate":1640665766036,"gmtModify":1640668247304,"author":{"id":3555190890634141,"idStr":"3555190890634141","authorId":3555190890634141,"authorIdStr":"3555190890634141","name":"ERIC KHOO SG","avatar":"https://static.tigerbbs.com/25b5481f56f8204f01f28c4192079f14","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":41,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Dont spread fud please</p></body></html>","htmlText":"<html><head></head><body><p>Dont spread fud please</p></body></html>","text":"Dont spread fud please","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696829532","repostId":1137683837,"repostType":4,"repost":{"id":"1137683837","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640664098,"share":"https://www.laohu8.com/m/news/1137683837?lang=&edition=full","pubTime":"2021-12-28 12:01","market":"hk","language":"en","title":"China's Kintor says interim analysis of COVID treatment trial misses statistical criteria","url":"https://stock-news.laohu8.com/highlight/detail?id=1137683837","media":"Reuters","summary":"BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III cli","content":"<p>BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.</p>\n<p>\"In a trial that had enrolled 348 people for interim analysis, a limited number of participants whose illness progressed from mild or moderate symptoms to the degree that required hospitalization was reported,\" a Kintor representative said on Monday.</p>\n<p>The low number resulted in the lack of statistical significance in data analysis between placebo group and the group where participants took the proxalutamide tablet, the representative said, without disclosing detailed readings.</p>\n<p>Kintor said in a filing on Monday that it will seek consent from authorities, including U.S. Food and Drug Administration, to amend clinical protocol and continue to enroll patients of higher risk, such as those who have not received a COVID-19 vaccination.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Kintor says interim analysis of COVID treatment trial misses statistical criteria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Kintor says interim analysis of COVID treatment trial misses statistical criteria\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-28 12:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.</p>\n<p>\"In a trial that had enrolled 348 people for interim analysis, a limited number of participants whose illness progressed from mild or moderate symptoms to the degree that required hospitalization was reported,\" a Kintor representative said on Monday.</p>\n<p>The low number resulted in the lack of statistical significance in data analysis between placebo group and the group where participants took the proxalutamide tablet, the representative said, without disclosing detailed readings.</p>\n<p>Kintor said in a filing on Monday that it will seek consent from authorities, including U.S. Food and Drug Administration, to amend clinical protocol and continue to enroll patients of higher risk, such as those who have not received a COVID-19 vaccination.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137683837","content_text":"BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.\n\"In a trial that had enrolled 348 people for interim analysis, a limited number of participants whose illness progressed from mild or moderate symptoms to the degree that required hospitalization was reported,\" a Kintor representative said on Monday.\nThe low number resulted in the lack of statistical significance in data analysis between placebo group and the group where participants took the proxalutamide tablet, the representative said, without disclosing detailed readings.\nKintor said in a filing on Monday that it will seek consent from authorities, including U.S. Food and Drug Administration, to amend clinical protocol and continue to enroll patients of higher risk, such as those who have not received a COVID-19 vaccination.","news_type":1},"isVote":1,"tweetType":1,"viewCount":940,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696829532"}
精彩评论